Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Total Liabilities (2019 - 2025)

Historic Total Liabilities for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $247.9 million.

  • Avidity Biosciences' Total Liabilities rose 8046.6% to $247.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $247.9 million, marking a year-over-year increase of 8046.6%. This contributed to the annual value of $138.9 million for FY2024, which is 872.13% up from last year.
  • Latest data reveals that Avidity Biosciences reported Total Liabilities of $247.9 million as of Q3 2025, which was up 8046.6% from $176.3 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Total Liabilities ranged from a high of $247.9 million in Q3 2025 and a low of $26.0 million during Q2 2021
  • Moreover, its 5-year median value for Total Liabilities was $55.7 million (2023), whereas its average is $89.8 million.
  • Per our database at Business Quant, Avidity Biosciences' Total Liabilities soared by 392.67% in 2021 and then surged by 14668.46% in 2024.
  • Quarter analysis of 5 years shows Avidity Biosciences' Total Liabilities stood at $46.2 million in 2021, then skyrocketed by 31.58% to $60.7 million in 2022, then surged by 110.44% to $127.8 million in 2023, then increased by 8.72% to $138.9 million in 2024, then soared by 78.46% to $247.9 million in 2025.
  • Its last three reported values are $247.9 million in Q3 2025, $176.3 million for Q2 2025, and $130.4 million during Q1 2025.